


Oregon PDAB reviews 16 drugs so far in 2025

Board will review insulin in October, vote on final list in early 2026

The Oregon Prescription Drug Affordability Board (PDAB) conducted prescription drug reviews throughout the summer and will complete the review phase this fall. To date, the board has reviewed 16 drugs from the list of 23. At the July meeting, the board reviewed Vraylar, Entresto, Ajovy, Emgality, Nurtec, and Ubrelvy. In August, the board reviewed Trelegy, Eliquis, Xarelto, Costenyx, and Creon. In September, the board reviewed Jardiance, Mounjaro, Ozempic, Rybelsus, and Trulicity. In October, the board will review seven insulin products: Basaglar KwikPen; Insulin Glargine-yfgn; Lantus; Lantus SoloStar; Semglee; Toujeo Max SoloStar, Toujeo SoloStar. The board is expected to vote on the final list in January 2026.

Scoring methodology: In August and September, the board discussed methodology for drug reviews with a scoring rubric and worksheet. Developed by PDAB senior policy analyst Cortnee Whitlock, these documents are tools board members can use to track the board meeting discussions about each drug. Board members have the option of using the scoring form when members vote on the drugs next year. These documents are posted on the PDAB website.



Glacier-carved Kiger Gorge in Southeastern Oregon.

Board vote: The board is expected to vote on the final list in January 2026. The vote was originally scheduled for November 2025, but the governor's office, in coordination with the chairs of the legislative health committees, approved an extension to allow additional time for review. During the Sept. 17 board meeting, members and staff discussed the drug review voting timeline and [reviewed a timeline document](#). Watch the discussion at video minute [03:16:24](#).

Final report for Oregon Legislature: In early spring 2026, the board will present a list to the Oregon Legislature identifying up to nine drugs and at least one insulin product board members have determined pose affordability challenges. The drug list will be included in a report for the Oregon Legislature. The board will review a draft of the report at the meeting on Feb. 18, 2026, and approve the final report on March 18, 2026.

Background on drug reviews: The board evaluates prescription drugs, including insulin products, to determine whether they pose affordability challenges for Oregonians and Oregon’s health care systems. Guided by state statute ([ORS 646A.694](#)) and administrative rules ([OAR 925-200-0010](#) and [OAR 925-200-0020](#)), the board applies specific criteria in its review process.

Drug review documents, minutes, videos: In the table below, the drugs are listed by the month of review. Click on the links to read reports about each drug, view the video discussion during board meetings, or read the meeting minutes. The October drug reports will be posted by Oct. 8, with the video posted by Oct. 16 and approved minutes posted after Nov. 19. Find a draft of the minutes included with the agenda materials posted one week before the meeting.

Public comment about drugs under review: To view the written public comments or listen to the speakers, open the drug report and scroll to the appendix at the end of the report.

Table of 2025 PDAB drug review resources and website links

Drug review group	Drug reports	Meeting videos	Meeting minutes
Vraylar, Entresto, Ajoyv, Emgality, Nurtec, Ubrelvy	July 16, 2025	July 16, 2025	July 16, 2025
Trelegy, Eliquis, Xarelto, Cosentyx, Creon	Aug. 20, 2025	Aug. 20, 2025	Aug. 20, 2025
Jardiance, Mounjaro, Ozempic, Rybelsus, Trulicity	Sept. 17, 2025	Sept. 17, 2025	Sept. 17, 2025
Basaglar KwikPen, Insulin Glargine-yfgn, Lantus, Lantus SoloStar, Semglee, Toujeo Max SoloStar, Toujeo SoloStar	Oct. 15, 2025	Oct. 15, 2025	Oct. 15, 2025

Michele Koder joins the board this month

Michele Koder, Pharm D and pharmacy director for the Multnomah County Health Department, is the newest member of the Prescription Drug Affordability Board. She was appointed by the governor and confirmed by the Oregon Senate on Oct. 1. Her first PDAB meeting will be Oct. 15.



Michele Koder

As a leader in Multnomah County's federally-qualified health center, Koder has diverse experience in budget development and management, clinical pharmacy services, and Medicaid managed care. Koder served on the Oregon Pain Management Commission as a

pharmacist member from 2013-21 and on the Oregon Health Resources Commission, participating in three of its subcommittees. She was also part of the Oregon Health Authority's statewide viral hepatitis planning group. Before joining Multnomah County's leadership team, she worked as assistant director of pharmacy for CareOregon and as clinical specialist for Medicaid programs for Oregon State University. Koder holds a doctorate degree in pharmacy from University of Rhode Island. She did her residency in family medicine and managed care at Oregon Health & Science University (OHSU).

PDAB members Daniel Hartung, Christopher Laman, Dan Kennedy reappointed to the board

The Oregon Senate confirmed the reappointment of PDAB members Dan Hartung, Chris Laman and Dan Kennedy.

Dan Hartung, Pharm D., is a pharmacy professor and researcher at Oregon State University. Chris Laman, Pharm D., is vice president of strategy and a pharmacist at Columbia Memorial Hospital in Astoria, and Dan Kennedy, RPh., is a retired pharmacist from Providence Health Plan in Portland and immediate past president of Oregon State Pharmacy Association.

They will serve four-year terms ending Dec. 31, 2029.

The eight-member board also includes Chair Shelley Bailey, MBA, CEO of Famlee fertility clinic; Vice Chair Amy Burns, Pharm D., vice president and pharmacist at AllCare Health, a coordinated care organization in Grants Pass; John Murray, RPh, a pharmacist and owner of Murrays Drugs in Heppner, Condon, and Boardman; Lauri Hoagland, NP, a nurse practitioner for a school-based health center in Central Point; and Michele Koder, pharmacy director for the Multnomah County Health Department.

[Click here to read board members bios.](#)

Sarah Young named new PDAB, DPT executive director



Sarah Young, MPH

Sarah Young, MPH, has been named the next executive director of the Prescription Drug Affordability Board and the Drug Price Transparency Program. Sarah has directed the Policy Research Division in the Federal Office of Rural Health Policy (FORHP) in the Health Resources and Services Administration since 2023. She managed a division of 17 people conducting FORHP's policy analysis, data analysis, research, and rural residency development efforts. Sarah's past work in FORHP has included managing Rural Health Clinic COVID-19 response programs, analyzing rural hospital and Critical Access Hospital (CAH) policy, tracking nationwide rural hospital closures, and coordinating the Medicare Rural Hospital Flexibility Program focused on improving CAH quality of care and operational efficiency.

Sarah was born and raised in Eastern Oregon and holds a master's degree in public health from Portland State University. She entered federal service in 2011 through the Presidential Management Fellows Program. Sarah is a gardener, knitter, and avid runner, currently training to run her seventh Marine Corps Marathon in late October.

Oregon PDAB will have three more board meetings in 2025

On Oct. 15, the board will conduct its phase four drug review and continue its discussion about policy recommendations to be included in the annual report for the Oregon Legislature. On Nov. 19, the board will review a draft of the annual report. On Dec. 17, the board will approve the final version of the annual report, which will be sent to the Legislature by Dec. 31. Click on the links below to register for the meetings:

[Oct. 15, 2025](#)

[Nov. 19, 2025](#)

[Dec. 17, 2025](#)

DPT public hearing on drug prices set for Dec. 4

The Oregon Drug Price Transparency (DPT) Program will hold the 2025 public hearing on prescription drug prices Thursday, Dec. 4, from 1:30 to 4 p.m. on Zoom. The Dec. 4 hearing will be moderated by Sen. Deb Patterson, Rep. Rob Nosse, and other members of the Oregon Legislature. To learn more about the hearing, visit the [DPT web page](#).

DPT invites patients, caregivers, and community members to share their experiences about the high cost of prescription drugs. The stories will be included in the Dec. 4 hearing. To share how prescription drug prices have affected you, complete the [form on the DPT web page](#). Check the box on the form if you would like to testify at the hearing.

Tell us your experience
dcbspa.org/RXSTORIES



Last year, the hearing featured panel discussions about who pays for drug advertising. Panelists included university professors, and representatives from public interest groups and pharmaceutical companies. The hearing also featured a panel discussion about drug rebates and how they help or harm consumers, and included insurance company and pharmacy representatives. DPT staff provided a summary of drug pricing information submitted by pharmaceutical manufacturers and insurance carriers operating in Oregon. DPT collects information annually and provides this data to PDAB about prescription drug price increases. Watch the 2024 DPT annual public hearing on prescription drug prices or read the 2024 DPT annual drug pricing report on the [DPT website](#).

More information about the Dec. 4 hearing is available on the [DPT web page](#).

PDAB announces 2026 board meetings

Here is the schedule of the Oregon PDAB meetings for 2026. Board meetings are held virtually on Zoom. Click on the links to register.

[Wednesday, Jan. 21](#)

[Wednesday, Feb. 18](#)

[Wednesday, March 18](#)

[Wednesday, April 15](#)

[Wednesday, May 20](#)

[Wednesday June 17](#)

[Wednesday July 15](#)

[Wednesday, Aug. 19](#)

[Wednesday, Sept. 16](#)

[Wednesday, Oct. 21](#)

[Wednesday, Nov. 18](#)

[Wednesday, Dec. 16](#)

Rx in the news

This column features news articles about prescription drugs.

[“Drummond secures \\$32M in settlement with CVS Caremark,”](#) by the Oklahoma Attorney General’s office, Sept. 9, 2025.

The state of Oklahoma reached a \$32 million settlement with CVS Caremark alleging the pharmacy benefit manager (PBM) withheld manufacturer discounts that should have been used to help reduce employee health plan costs. CVS Caremark is the PBM that manages prescription drug benefits for the state’s employee health plan.

[“Attorney General’s Office sues CVS Caremark for PBM violations,”](#) by Oklahoma Attorney General’s office, Jan. 23, 2025.

The state is suing its PBM for reimbursing 200 prescription claims filled by 15 Oklahoma pharmacies below acquisition cost, which violates state law. The pharmacies “lost thousands of dollars to fill these prescriptions and help patients get the medications they needed.” One rural pharmacy filled nearly half of the 200 prescriptions that were reimbursed under cost. The pharmacies filed appeals after receiving their reimbursements, but CVS Caremark denied them, claiming a lower acquisition price was available.